1.3M XNAS Volume
XNAS 14 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Hans P. Hull | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 40,150 | 251,708 | - | 0 | Common Stock | |
| Hans P. Hull | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 80,300 | 80,300 | - | - | Stock Option (Right to Buy) | |
| Eric Lefebvre | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 45,650 | 240,224 | - | 0 | Common Stock | |
| Eric Lefebvre | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 91,300 | 91,300 | - | - | Stock Option (Right to Buy) | |
| Bernard Coulie | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 325,000 | 325,000 | - | - | Stock Option (Right to Buy) | |
| Bernard Coulie | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 162,500 | 593,017 | - | 0 | Common Stock | |
| Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 113,300 | 113,300 | - | - | Stock Option (Right to Buy) | |
| Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 56,650 | 319,258 | - | 0 | Common Stock | |
| Mike Ouimette | General Counsel & Corp. Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Mike Ouimette | General Counsel & Corp. Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 35,000 | 105,544 | - | 0 | Common Stock | |
| Lily Cheung | Chief Human Resource Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 51,750 | 51,750 | - | - | Stock Option (Right to Buy) | |
| Lily Cheung | Chief Human Resource Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 25,875 | 50,425 | - | 0 | Common Stock | |
| Hans P. Hull | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 11.20 per share. | 17 Jan 2025 | 15,936 | 211,558 | - | 11.2 | 178,501 | Common Stock |
| Eric Lefebvre | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.20 per share. | 17 Jan 2025 | 18,478 | 194,574 | - | 11.2 | 206,974 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.20 per share. | 17 Jan 2025 | 52,419 | 430,517 | - | 11.2 | 587,150 | Common Stock |
| Keith Cummings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.20 per share. | 17 Jan 2025 | 20,148 | 262,608 | - | 11.2 | 225,680 | Common Stock |
| Mike Ouimette | General Counsel & Corp. Secy | Sale of securities on an exchange or to another person at price $ 11.20 per share. | 17 Jan 2025 | 13,270 | 80,774 | - | 11.2 | 148,639 | Common Stock |
| Mike Ouimette | General Counsel & Corp. Secy | Sale of securities on an exchange or to another person at price $ 10.99 per share. | 17 Jan 2025 | 10,230 | 70,544 | - | 11.0 | 112,462 | Common Stock |
| Lily Cheung | Chief Human Resource Officer | Sale of securities on an exchange or to another person at price $ 11.20 per share. | 17 Jan 2025 | 3,740 | 24,550 | - | 11.2 | 41,892 | Common Stock |
| Hans P. Hull | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 11.56 per share. | 10 Jul 2024 | 9,900 | 227,494 | - | 11.6 | 114,444 | Common Stock |
| Eric Lefebvre | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 11.56 per share. | 10 Jul 2024 | 12,319 | 213,052 | - | 11.6 | 142,408 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 11.56 per share. | 10 Jul 2024 | 38,710 | 482,936 | - | 11.6 | 447,488 | Common Stock |
| Keith Cummings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.56 per share. | 10 Jul 2024 | 10,911 | 282,115 | - | 11.6 | 126,131 | Common Stock |
| Mike Ouimette | General Counsel & Corp. Secy | Sale of securities on an exchange or to another person at price $ 11.56 per share. | 10 Jul 2024 | 7,656 | 94,044 | - | 11.6 | 88,503 | Common Stock |
| Hans P. Hull | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jul 2024 | 19,337 | 237,394 | - | 0 | Common Stock | |
| Eric Lefebvre | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jul 2024 | 24,063 | 225,371 | - | 0 | Common Stock | |
| Bernard Coulie | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jul 2024 | 75,625 | 521,646 | - | 0 | Common Stock | |
| Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jul 2024 | 21,313 | 293,026 | - | 0 | Common Stock | |
| Mike Ouimette | General Counsel & Corp. Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jul 2024 | 14,954 | 101,700 | - | 0 | Common Stock | |
| Hoyoung Huh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 26,764 | 26,764 | - | - | Common Stock (Right to Buy) | |
| David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 26,764 | 26,764 | - | - | Common Stock (Right to Buy) | |
| Thomas A. McCourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 26,764 | 26,764 | - | - | Common Stock (Right to Buy) | |
| Gayle Crowell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 26,764 | 26,764 | - | - | Common Stock (Right to Buy) | |
| Suzanne L. Bruhn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 26,764 | 26,764 | - | - | Common Stock (Right to Buy) | |
| John T. Curnutte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 26,764 | 26,764 | - | - | Common Stock (Right to Buy) | |
| Darren S. Cline | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 26,764 | 26,764 | - | - | Common Stock (Right to Buy) | |
| Smital Shah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 26,764 | 26,764 | - | - | Common Stock (Right to Buy) | |
| Steven E. Krognes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 53,528 | 53,528 | - | - | Common Stock (Right to Buy) | |
| Katharine Knobil | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 26,764 | 26,764 | - | - | Common Stock (Right to Buy) | |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 May 2024 | 21,000 | 76,047 | - | - | Stock Option (Right to Buy) | |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 02 May 2024 | 21,000 | 271,713 | - | 2.1 | 43,680 | Common Stock |
| Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 55,250 | 249,855 | - | 0 | Common Stock | |
| P. Hans Hull | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 63,000 | 63,000 | - | - | Stock Option (Right to Buy) | |
| Cummings Keith | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 110,500 | 110,500 | - | - | Stock Option (Right to Buy) | |
| Bernard Coulie | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 128,150 | 444,532 | - | 0 | Common Stock | |
| Cheung Lily | Chief Human Resource Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 26,000 | 26,795 | - | 0 | Common Stock | |
| Bernard Coulie | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 256,300 | 256,300 | - | - | Stock Option (Right to Buy) | |
| Mike Ouimette | General Counsel & Corp. Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 31,500 | 86,746 | - | 0 | Common Stock | |
| Ouimette Mike | General Counsel & Corp. Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 63,000 | 63,000 | - | - | Stock Option (Right to Buy) | |
| Cheung Lily | Chief Human Resource Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 52,000 | 52,000 | - | - | Stock Option (Right to Buy) | |
| Lefebvre Eric | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 85,800 | 85,800 | - | - | Stock Option (Right to Buy) | |
| Hans Hull P. | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 31,500 | 216,569 | - | 0 | Common Stock | |
| Eric Lefebvre | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 42,900 | 199,820 | - | 0 | Common Stock | |
| Cummings Keith | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.23 per share. | 17 Jan 2024 | 9,781 | 194,605 | - | 17.2 | 168,527 | Common Stock |
| Lefebvre Eric | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 17.23 per share. | 17 Jan 2024 | 10,295 | 156,920 | - | 17.2 | 177,383 | Common Stock |
| Hans Hull P. | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 17.23 per share. | 17 Jan 2024 | 9,786 | 185,069 | - | 17.2 | 168,613 | Common Stock |
| Ouimette Mike | General Counsel & Corp. Secy | Sale of securities on an exchange or to another person at price $ 17.23 per share. | 17 Jan 2024 | 5,197 | 55,246 | - | 17.2 | 89,544 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 17.23 per share. | 17 Jan 2024 | 25,721 | 316,382 | - | 17.2 | 443,173 | Common Stock |
| Hans P. Hull | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 03 Aug 2023 | 13,069 | 206,114 | - | 20 | 261,380 | Common Stock |
| Hans P. Hull | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 8,791 | 31,367 | - | - | Common Stock (Right to Buy) | |
| Hans P. Hull | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2023 | 1,800 | 40,158 | - | - | Common Stock (Right to Buy) | |
| Hans P. Hull | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 20.01 per share. | 03 Aug 2023 | 20,050 | 194,855 | - | 20.0 | 401,201 | Common Stock |
| Hans P. Hull | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 03 Aug 2023 | 8,791 | 214,905 | - | 2.1 | 18,285 | Common Stock |
| Hans P. Hull | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 03 Aug 2023 | 1,800 | 206,114 | - | 20 | 36,000 | Common Stock |
| Hans P. Hull | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 03 Aug 2023 | 1,800 | 207,914 | - | 2.1 | 3,744 | Common Stock |
| Mike Ouimette | General Counsel & Corp. Secy | Sale of securities on an exchange or to another person at price $ 17.55 per share. | 20 Jul 2023 | 4,755 | 60,443 | - | 17.5 | 83,450 | Common Stock |
| Hans P. Hull | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 18.01 per share. | 17 Jul 2023 | 17,937 | 219,183 | - | 18.0 | 323,029 | Common Stock |
| Eric Lefebvre | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 18.01 per share. | 17 Jul 2023 | 22,321 | 167,215 | - | 18.0 | 401,981 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 18.01 per share. | 17 Jul 2023 | 70,150 | 342,103 | - | 18.0 | 1,263,338 | Common Stock |
| Keith Cummings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 18.01 per share. | 17 Jul 2023 | 19,771 | 203,999 | - | 18.0 | 356,058 | Common Stock |
| Mike Ouimette | General Counsel & Corp. Secy | Sale of securities on an exchange or to another person at price $ 18.01 per share. | 17 Jul 2023 | 12,778 | 65,198 | - | 18.0 | 230,120 | Common Stock |
| Hans P. Hull | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 35,156 | 237,120 | - | 0 | Common Stock | |
| Eric Lefebvre | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 43,750 | 189,536 | - | 0 | Common Stock | |
| Bernard Coulie | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 137,500 | 412,253 | - | 0 | Common Stock | |
| Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 38,750 | 223,770 | - | 0 | Common Stock | |
| Mike Ouimette | General Counsel & Corp. Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2023 | 27,187 | 77,976 | - | 0 | Common Stock | |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 09 Jun 2023 | 5,800 | 154,270 | - | 2.1 | 12,064 | Common Stock |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2023 | 5,800 | 127,797 | - | - | Stock Option (Right to Buy) | |
| Hoyoung Huh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Thomas A. McCourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Gayle Crowell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Suzanne L. Bruhn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| John T. Curnutte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Darren S. Cline | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Smital Shah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Katharine Knobil | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 14,000 | 14,000 | - | - | Stock Option (Right to Buy) | |
| Hans P. Hull | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 26.52 per share. | 30 Mar 2023 | 9,036 | 201,964 | - | 26.5 | 239,643 | Common Stock |
| Eric Lefebvre | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 26.52 per share. | 30 Mar 2023 | 11,245 | 145,786 | - | 26.5 | 298,228 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 26.52 per share. | 30 Mar 2023 | 35,339 | 274,753 | - | 26.5 | 937,222 | Common Stock |
| Keith Cummings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 26.52 per share. | 30 Mar 2023 | 9,960 | 148,470 | - | 26.5 | 264,148 | Common Stock |
| Mike Ouimette | General Counsel & Corp. Secy | Sale of securities on an exchange or to another person at price $ 26.52 per share. | 30 Mar 2023 | 4,874 | 53,666 | - | 26.5 | 129,263 | Common Stock |
| Mike Ouimette | General Counsel & Corp. Secy | Sale of securities on an exchange or to another person at price $ 27.46 per share. | 30 Mar 2023 | 200 | 50,789 | - | 27.5 | 5,491 | Common Stock |
| Mike Ouimette | General Counsel & Corp. Secy | Sale of securities on an exchange or to another person at price $ 26.74 per share. | 30 Mar 2023 | 2,677 | 50,989 | - | 26.7 | 71,575 | Common Stock |
| Hans P. Hull | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2023 | 17,578 | 211,000 | - | 0 | Common Stock | |
| Eric Lefebvre | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2023 | 21,874 | 157,031 | - | 0 | Common Stock | |
| Bernard Coulie | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2023 | 68,749 | 310,092 | - | 0 | Common Stock | |
| Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2023 | 19,375 | 158,430 | - | 0 | Common Stock | |
| Mike Ouimette | General Counsel & Corp. Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Mar 2023 | 13,593 | 58,540 | - | 0 | Common Stock | |
| Thomas A. McCourt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Darren S. Cline | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 34.08 per share. | 02 Feb 2023 | 5,262 | 240,112 | - | 34.1 | 179,312 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.22 per share. | 02 Feb 2023 | 15,000 | 255,112 | - | 6.2 | 93,300 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 34.96 per share. | 02 Feb 2023 | 1,605 | 240,112 | - | 35.0 | 56,105 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 34.13 per share. | 02 Feb 2023 | 13,395 | 241,717 | - | 34.1 | 457,124 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.22 per share. | 02 Feb 2023 | 15,000 | 255,112 | - | 6.2 | 93,300 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 33.36 per share. | 02 Feb 2023 | 9,738 | 245,374 | - | 33.4 | 324,888 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 15,000 | 342,262 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2023 | 15,000 | 327,262 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 15,000 | 357,262 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 15,000 | 157,380 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 10,539 | 146,841 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 4,461 | 372,262 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 34.78 per share. | 30 Jan 2023 | 5,440 | 240,217 | - | 34.8 | 189,192 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 34.15 per share. | 30 Jan 2023 | 9,455 | 245,657 | - | 34.1 | 322,841 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.22 per share. | 30 Jan 2023 | 15,000 | 255,112 | - | 6.2 | 93,300 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 34.92 per share. | 30 Jan 2023 | 15,000 | 240,112 | - | 34.9 | 523,755 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.22 per share. | 30 Jan 2023 | 4,461 | 255,112 | - | 6.2 | 27,747 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 30 Jan 2023 | 10,539 | 250,651 | - | 2.1 | 21,921 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 34.66 per share. | 30 Jan 2023 | 3,605 | 240,112 | - | 34.7 | 124,938 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 33.98 per share. | 30 Jan 2023 | 11,395 | 243,717 | - | 34.0 | 387,177 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 30 Jan 2023 | 15,000 | 255,112 | - | 2.1 | 31,200 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 35.55 per share. | 30 Jan 2023 | 105 | 240,112 | - | 35.6 | 3,733 | Common Stock |
| Hans P. Hull | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 76,200 | 76,200 | - | - | Stock Option (right to buy) | |
| Hans P. Hull | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 54,000 | 192,191 | - | 0 | Common Stock | |
| Eric Lefebvre | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 80,000 | 80,000 | - | - | Stock Option (right to buy) | |
| Eric Lefebvre | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 57,000 | 133,926 | - | 0 | Common Stock | |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 36.64 per share. | 25 Jan 2023 | 221 | 409,317 | - | 36.6 | 8,097 | Common Stock |
| Bernard Coulie | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 146,300 | 240,112 | - | 0 | Common Stock | |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 25 Jan 2023 | 15,000 | 255,112 | - | 2.1 | 31,200 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 35.29 per share. | 25 Jan 2023 | 15,000 | 240,112 | - | 35.3 | 529,367 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 35.10 per share. | 25 Jan 2023 | 15,000 | 419,317 | - | 35.1 | 526,425 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 25 Jan 2023 | 15,000 | 255,112 | - | 2.1 | 31,200 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 35.42 per share. | 25 Jan 2023 | 8,698 | 246,414 | - | 35.4 | 308,046 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 36.06 per share. | 25 Jan 2023 | 6,302 | 240,112 | - | 36.1 | 227,243 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 35.09 per share. | 25 Jan 2023 | 9,779 | 409,538 | - | 35.1 | 343,158 | Common Stock |
| Bernard Coulie | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 206,300 | 206,300 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2023 | 15,000 | 187,380 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2023 | 15,000 | 172,380 | - | - | Stock Option (right to buy) | |
| Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 76,200 | 76,200 | - | - | Stock Option (right to buy) | |
| Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 54,000 | 138,424 | - | 0 | Common Stock | |
| Mike Ouimette | General Counsel & Corp. Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| Mike Ouimette | General Counsel & Corp. Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jan 2023 | 39,000 | 44,947 | - | 0 | Common Stock | |
| Eric Lefebvre | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 34.48 per share. | 23 Jan 2023 | 67,500 | 76,926 | - | 34.5 | 2,327,630 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2023 | 15,000 | 217,380 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2023 | 15,000 | 232,380 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 33.29 per share. | 23 Jan 2023 | 1,696 | 93,812 | - | 33.3 | 56,459 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 32.40 per share. | 23 Jan 2023 | 13,304 | 95,508 | - | 32.4 | 431,058 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 23 Jan 2023 | 15,000 | 108,812 | - | 2.1 | 31,200 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 30.89 per share. | 23 Jan 2023 | 15,000 | 93,812 | - | 30.9 | 463,389 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 23 Jan 2023 | 15,000 | 108,812 | - | 2.1 | 31,200 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 23 Jan 2023 | 15,000 | 434,317 | - | 35 | 525,000 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 34.93 per share. | 23 Jan 2023 | 4,850 | 93,812 | - | 34.9 | 169,405 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 33.71 per share. | 23 Jan 2023 | 10,150 | 98,662 | - | 33.7 | 342,163 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 23 Jan 2023 | 15,000 | 108,812 | - | 2.1 | 31,200 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2023 | 15,000 | 202,380 | - | - | Stock Option (right to buy) | |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2023 | 17,500 | 18,198 | - | - | Stock Option (right to buy) | |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.22 per share. | 23 Jan 2023 | 17,500 | 114,424 | - | 6.2 | 108,850 | Common Stock |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 23 Jan 2023 | 12,500 | 96,924 | - | 2.1 | 26,000 | Common Stock |
| Keith Cummings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 23 Jan 2023 | 30,000 | 84,424 | - | 35 | 1,050,000 | Common Stock |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2023 | 12,500 | 133,597 | - | - | Stock Option (right to buy) | |
| Mike Ouimette | General Counsel & Corp. Secy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2023 | 10,000 | 98,240 | - | - | Stock Option (right to buy) | |
| Mike Ouimette | General Counsel & Corp. Secy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jan 2023 | 10,000 | 77,000 | - | - | Stock Option (right to buy) | |
| Mike Ouimette | General Counsel & Corp. Secy | Sale of securities on an exchange or to another person at price $ 34.19 per share. | 23 Jan 2023 | 20,000 | 5,947 | - | 34.2 | 683,878 | Common Stock |
| Mike Ouimette | General Counsel & Corp. Secy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.32 per share. | 23 Jan 2023 | 10,000 | 25,947 | - | 24.3 | 243,200 | Common Stock |
| Mike Ouimette | General Counsel & Corp. Secy | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.86 per share. | 23 Jan 2023 | 10,000 | 15,947 | - | 11.9 | 118,600 | Common Stock |
| Lily Cheung | Chief Human Resource Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2023 | 123,000 | 123,000 | - | - | Stock Option (Right to Buy) | |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 06 Jan 2023 | 5,000 | 98,812 | - | 2.1 | 10,400 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.04 per share. | 06 Jan 2023 | 15,000 | 93,812 | - | 19.0 | 285,584 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2023 | 5,000 | 247,380 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2023 | 15,000 | 252,380 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.17 per share. | 06 Jan 2023 | 5,000 | 93,812 | - | 19.2 | 95,829 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 06 Jan 2023 | 15,000 | 108,812 | - | 2.1 | 31,200 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 15,000 | 282,380 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 03 Jan 2023 | 15,000 | 108,812 | - | 2.1 | 31,200 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 03 Jan 2023 | 15,000 | 108,812 | - | 2.1 | 31,200 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.06 per share. | 03 Jan 2023 | 15,000 | 93,812 | - | 19.1 | 285,941 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.33 per share. | 03 Jan 2023 | 15,000 | 93,812 | - | 19.3 | 289,952 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 15,000 | 267,380 | - | - | Stock Option (right to buy) | |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 22 Dec 2022 | 4,000 | 84,424 | - | 2.1 | 8,320 | Common Stock |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Dec 2022 | 4,000 | 146,097 | - | - | Stock Option (right to buy) | |
| Mike Ouimette | General Counsel & Corp. Secy | Sale of securities on an exchange or to another person at price $ 19.38 per share. | 22 Dec 2022 | 2,928 | 5,947 | - | 19.4 | 56,731 | Common Stock |
| Eric Lefebvre | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2022 | 21,876 | 155,313 | - | 0 | Common Stock | |
| Eric Lefebvre | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 19.10 per share. | 19 Dec 2022 | 10,887 | 144,426 | - | 19.1 | 207,968 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 19.10 per share. | 19 Dec 2022 | 34,212 | 93,812 | - | 19.1 | 653,531 | Common Stock |
| Bernard Coulie | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2022 | 68,751 | 128,024 | - | 0 | Common Stock | |
| Keith Cummings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.10 per share. | 19 Dec 2022 | 9,643 | 80,424 | - | 19.1 | 184,204 | Common Stock |
| Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2022 | 19,375 | 90,067 | - | 0 | Common Stock | |
| Mike Ouimette | General Counsel & Corp. Secy | Sale of securities on an exchange or to another person at price $ 19.10 per share. | 19 Dec 2022 | 4,719 | 8,875 | - | 19.1 | 90,144 | Common Stock |
| Mike Ouimette | General Counsel & Corp. Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2022 | 13,594 | 13,594 | - | 0 | Common Stock | |
| Eric Lefebvre | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 25.05 per share. | 25 Oct 2022 | 5,000 | 133,437 | - | 25.0 | 125,241 | Common Stock |
| Katharine Knobil | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2022 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Sep 2022 | 12,502 | 297,380 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 12 Sep 2022 | 12,502 | 71,775 | - | 2.1 | 26,004 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 22.54 per share. | 12 Sep 2022 | 12,502 | 59,273 | - | 22.5 | 281,851 | Common Stock |
| Eric Lefebvre | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 11 Jul 2022 | 3,000 | 138,436 | - | 20 | 60,000 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2022 | 12,498 | 309,882 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 11 Jul 2022 | 15,000 | 74,273 | - | 2.1 | 31,200 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 22.50 per share. | 11 Jul 2022 | 15,000 | 59,273 | - | 22.5 | 337,500 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 11 Jul 2022 | 12,498 | 71,771 | - | 2.1 | 25,996 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 22.50 per share. | 11 Jul 2022 | 12,498 | 59,273 | - | 22.5 | 281,205 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2022 | 15,000 | 322,380 | - | - | Stock Option (right to buy) | |
| Hoyoung Huh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Gayle Crowell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Suzanne L. Bruhn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| John T. Curnutte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Smital Shah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Neil Exter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| Eric Lefebvre | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 140,000 | 140,000 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 440,000 | 440,000 | - | - | Stock Option (right to buy) | |
| Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 124,000 | 124,000 | - | - | Stock Option (right to buy) | |
| Mike Ouimette | General Counsel & Corp. Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2022 | 87,000 | 87,000 | - | - | Stock Option (right to buy) | |
| Charles J. Homcy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 13,286 | 13,286 | - | - | Stock Option (right to buy) | |
| Hoyoung Huh | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 13,286 | 13,286 | - | - | Stock Option (right to buy) | |
| David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 13,286 | 13,286 | - | - | Stock Option (right to buy) | |
| Gayle Crowell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 13,286 | 13,286 | - | - | Stock Option (right to buy) | |
| Suzanne L. Bruhn | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 13,286 | 13,286 | - | - | Stock Option (right to buy) | |
| John T. Curnutte | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 13,286 | 13,286 | - | - | Stock Option (right to buy) | |
| Smital Shah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 13,286 | 13,286 | - | - | Stock Option (right to buy) | |
| Neil Exter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jun 2021 | 13,286 | 13,286 | - | - | Stock Option (right to buy) | |
| Eric Lefebvre | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.43 per share. | 18 Jun 2021 | 3,728 | 137,102 | - | 29.4 | 109,718 | Common Stock |
| Eric Lefebvre | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.23 per share. | 18 Jun 2021 | 22 | 137,080 | - | 30.2 | 665 | Common Stock |
| Eric Lefebvre | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.62 per share. | 18 Jun 2021 | 8,750 | 140,830 | - | 28.6 | 250,438 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 33.69 per share. | 14 Jun 2021 | 243 | 449,317 | - | 33.7 | 8,186 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 32.98 per share. | 14 Jun 2021 | 3,757 | 449,560 | - | 33.0 | 123,916 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 28.53 per share. | 14 May 2021 | 2,997 | 453,820 | - | 28.5 | 85,499 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 29.28 per share. | 14 May 2021 | 503 | 453,317 | - | 29.3 | 14,726 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 30.33 per share. | 13 Apr 2021 | 3,500 | 456,817 | - | 30.3 | 106,161 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 6,000 | 337,380 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 13 Apr 2021 | 6,000 | 54,840 | - | 2.1 | 12,480 | Common Stock |
| Eric Lefebvre | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 39.78 per share. | 18 Mar 2021 | 1,135 | 149,580 | - | 39.8 | 45,150 | Common Stock |
| Eric Lefebvre | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 39.38 per share. | 18 Mar 2021 | 11,365 | 150,715 | - | 39.4 | 447,528 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 39.69 per share. | 15 Mar 2021 | 178 | 460,317 | - | 39.7 | 7,064 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 38.75 per share. | 15 Mar 2021 | 2,000 | 460,495 | - | 38.8 | 77,501 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 38.03 per share. | 15 Mar 2021 | 1,322 | 462,495 | - | 38.0 | 50,270 | Common Stock |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 05 Mar 2021 | 20,000 | 47,621 | - | 2.1 | 41,600 | Common Stock |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2021 | 20,000 | 170,097 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 32.87 per share. | 16 Feb 2021 | 2,100 | 464,017 | - | 32.9 | 69,018 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 34.07 per share. | 16 Feb 2021 | 200 | 463,817 | - | 34.1 | 6,814 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 32.10 per share. | 16 Feb 2021 | 1,200 | 466,117 | - | 32.1 | 38,520 | Common Stock |
| Eric Lefebvre | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2021 | 73,250 | 73,250 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2021 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2021 | 74,250 | 74,250 | - | - | Stock Option (right to buy) | |
| Barbara Howes | Chief Human Resource Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2021 | 42,500 | 42,500 | - | - | Stock Option (right to buy) | |
| Mike Ouimette | General Counsel & Corp. Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2021 | 15,520 | 15,520 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 26.20 per share. | 14 Jan 2021 | 2,870 | 467,947 | - | 26.2 | 75,180 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 27.21 per share. | 14 Jan 2021 | 630 | 467,317 | - | 27.2 | 17,145 | Common Stock |
| David E.I. Pyott | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2021 | 26,573 | 26,573 | - | - | Stock Option (right to buy) | |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2020 | 4,500 | 190,097 | - | - | Stock Option (right to buy) | |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 21 Dec 2020 | 4,500 | 27,621 | - | 2.1 | 9,360 | Common Stock |
| Eric Lefebvre | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 26.98 per share. | 18 Dec 2020 | 5,712 | 162,080 | - | 27.0 | 154,110 | Common Stock |
| Eric Lefebvre | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 26.17 per share. | 18 Dec 2020 | 6,788 | 167,792 | - | 26.2 | 177,642 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 27.86 per share. | 14 Dec 2020 | 337 | 470,817 | - | 27.9 | 9,388 | Common Stock |
| Bernard Coulie | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 27.32 per share. | 14 Dec 2020 | 3,163 | 471,154 | - | 27.3 | 86,402 | Common Stock |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.22 per share. | 01 Dec 2020 | 7,143 | 41,855 | - | 6.2 | 44,429 | Common Stock |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 01 Dec 2020 | 11,591 | 34,712 | - | 2.1 | 24,109 | Common Stock |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 7,143 | 35,698 | - | - | Stock Option (right to buy) | |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 11,591 | 194,597 | - | - | Stock Option (right to buy) | |
| Keith Cummings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.72 per share. | 01 Dec 2020 | 846 | 23,121 | - | 30.7 | 25,989 | Common Stock |
| Keith Cummings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 30.21 per share. | 01 Dec 2020 | 14,901 | 23 | - | 30.2 | 450,159 | Common Stock |
| Keith Cummings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 29.07 per share. | 01 Dec 2020 | 1,848 | 38,868 | - | 29.1 | 53,721 | Common Stock |
| Keith Cummings | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 28.24 per share. | 01 Dec 2020 | 1,139 | 40,716 | - | 28.2 | 32,165 | Common Stock |
| Mike Ouimette | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Oct 2020 | 108,240 | 108,240 | - | - | Stock Option (right to buy) | |
| Hoyoung Huh | Director | 05 Jun 2020 | 1,000,000 | 0 | - | - | Series A Preferred Stock | ||
| Hoyoung Huh | Director | 05 Jun 2020 | 139,860 | 239,619 | - | - | Common Stock | ||
| Neil Exter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 26,573 | 26,573 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 377,336 | 377,336 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | 05 Jun 2020 | 25,397 | 474,317 | - | - | Common Stock | ||
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 05 Jun 2020 | 48,227 | 48,840 | - | 2.1 | 100,312 | Common Stock |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.22 per share. | 05 Jun 2020 | 613 | 613 | - | 6.2 | 3,813 | Common Stock |
| Bernard Coulie | Director, President and CEO | 05 Jun 2020 | 181,594 | 0 | - | - | Series B Preferred Stock | ||
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2020 | 48,227 | 343,380 | - | - | Stock Option (right to buy) | |
| Bernard Coulie | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2020 | 613 | 376,723 | - | - | Stock Option (right to buy) | |
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jun 2020 | 19,300 | 206,188 | - | - | Stock Option (right to buy) | |
| Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 27,322 | 27,322 | - | - | Series C Preferred Stock | |
| Keith Cummings | Chief Financial Officer | 05 Jun 2020 | 3,821 | 23,121 | - | - | Common Stock | ||
| Keith Cummings | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.08 per share. | 05 Jun 2020 | 19,300 | 19,300 | - | 2.1 | 40,144 | Common Stock |
| Keith Cummings | Chief Financial Officer | 05 Jun 2020 | 27,322 | 0 | - | - | Series C Preferred Stock | ||
| Keith Cummings | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 42,841 | 42,841 | - | - | Stock Option (right to buy) | |
| Barbara Howes | Chief Human Resource Officer | 05 Jun 2020 | 3,821 | 24,799 | - | - | Common Stock | ||
| Barbara Howes | Chief Human Resource Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 27,322 | 27,322 | - | - | Series C Preferred Stock | |
| Barbara Howes | Chief Human Resource Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 7,584 | 7,584 | - | - | Stock Option (right to buy) | |
| Barbara Howes | Chief Human Resource Officer | 05 Jun 2020 | 27,322 | 0 | - | - | Series C Preferred Stock |